Nasdaq Grants Aprea Therapeutics 180-Day Extension to Regain $1.00 Bid Compliance
APRE sits 15% above its 52-week low of $0.548 on light trading volume (0.2× avg).
Summary
Nasdaq granted Aprea Therapeutics an additional 180 days, until January 19, 2027, to regain compliance with the $1.00 minimum bid price requirement. The stock currently trades at $0.63.
Key Events · Legal and Risk Events · APRE
-
Nasdaq Extends Compliance Deadline
Nasdaq granted Aprea an additional 180 calendar days, until January 19, 2027, to regain compliance with the $1.00 minimum bid price requirement, extending the prior July 22, 2026 deadline.
-
Stock Trades Below $1.00 Threshold
Aprea's common stock currently trades at $0.63, well below the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market.
-
Reverse Split Approved as Compliance Tool
Shareholders previously approved a reverse stock split on June 17, 2026, empowering the board to implement it to boost the share price above $1.00 and maintain Nasdaq listing.
-
Delisting Risk Remains
If compliance is not demonstrated by January 19, 2027, Nasdaq will issue a delisting notice, though the company may appeal to a hearings panel.
Analysis · APRE · Life Sciences
Aprea Therapeutics received a lifeline from Nasdaq, extending its deadline to regain the $1.00 minimum bid price to January 19, 2027. The stock currently trades at $0.63, well below the threshold. While the extension buys time, the company must still execute a reverse stock split or see its share price appreciate significantly to avoid delisting. The recent shareholder approval of a reverse split gives the board a tool to force compliance, but the clock is ticking.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APRE was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8M. The 52-week trading range was $0.55 to $2.22. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.